IL199242A - Elphrazole crystalline hydrophilic hydrate, medicinal preparations containing it to inhibit gastric acid secretion, and its use in the preparation of drugs to treat gastrointestinal infections - Google Patents

Elphrazole crystalline hydrophilic hydrate, medicinal preparations containing it to inhibit gastric acid secretion, and its use in the preparation of drugs to treat gastrointestinal infections

Info

Publication number
IL199242A
IL199242A IL199242A IL19924209A IL199242A IL 199242 A IL199242 A IL 199242A IL 199242 A IL199242 A IL 199242A IL 19924209 A IL19924209 A IL 19924209A IL 199242 A IL199242 A IL 199242A
Authority
IL
Israel
Prior art keywords
crystalline
ilaprazole
intensity
solvate
racemic
Prior art date
Application number
IL199242A
Other languages
English (en)
Hebrew (he)
Original Assignee
Il Yang Pharmaceutical Company Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Il Yang Pharmaceutical Company Ltd filed Critical Il Yang Pharmaceutical Company Ltd
Publication of IL199242A publication Critical patent/IL199242A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
IL199242A 2006-12-29 2009-06-08 Elphrazole crystalline hydrophilic hydrate, medicinal preparations containing it to inhibit gastric acid secretion, and its use in the preparation of drugs to treat gastrointestinal infections IL199242A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US87760806P 2006-12-29 2006-12-29
US88749907P 2007-01-31 2007-01-31
PCT/US2007/089137 WO2008083341A1 (en) 2006-12-29 2007-12-28 Crystalline forms of solvated ilaprazole

Publications (1)

Publication Number Publication Date
IL199242A true IL199242A (en) 2013-10-31

Family

ID=39313094

Family Applications (2)

Application Number Title Priority Date Filing Date
IL199242A IL199242A (en) 2006-12-29 2009-06-08 Elphrazole crystalline hydrophilic hydrate, medicinal preparations containing it to inhibit gastric acid secretion, and its use in the preparation of drugs to treat gastrointestinal infections
IL199234A IL199234A (en) 2006-12-29 2009-06-08 A crystalline form of intrinsic elaprazole, medicinal preparations containing it to inhibit gastric acid secretion, and its use in the preparation of drugs to treat infections of the digestive system @

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL199234A IL199234A (en) 2006-12-29 2009-06-08 A crystalline form of intrinsic elaprazole, medicinal preparations containing it to inhibit gastric acid secretion, and its use in the preparation of drugs to treat infections of the digestive system @

Country Status (19)

Country Link
US (4) US7989632B2 (US07585860-20090908-C00112.png)
EP (2) EP2102191B1 (US07585860-20090908-C00112.png)
JP (2) JP5315253B2 (US07585860-20090908-C00112.png)
KR (3) KR101052387B1 (US07585860-20090908-C00112.png)
CN (2) CN101687848B (US07585860-20090908-C00112.png)
AU (2) AU2007341984B2 (US07585860-20090908-C00112.png)
CA (2) CA2674358C (US07585860-20090908-C00112.png)
DK (1) DK2102192T3 (US07585860-20090908-C00112.png)
ES (1) ES2398846T3 (US07585860-20090908-C00112.png)
HK (2) HK1140483A1 (US07585860-20090908-C00112.png)
IL (2) IL199242A (US07585860-20090908-C00112.png)
MX (2) MX2009006529A (US07585860-20090908-C00112.png)
MY (2) MY146462A (US07585860-20090908-C00112.png)
NO (2) NO20092398L (US07585860-20090908-C00112.png)
NZ (2) NZ577129A (US07585860-20090908-C00112.png)
PL (1) PL2102192T3 (US07585860-20090908-C00112.png)
PT (1) PT2102192E (US07585860-20090908-C00112.png)
RU (2) RU2466129C2 (US07585860-20090908-C00112.png)
WO (2) WO2008083333A1 (US07585860-20090908-C00112.png)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101144600B1 (ko) * 2009-12-08 2012-05-16 일양약품주식회사 일라프라졸의 결정형 ａ, ｂ의 제조방법 및 이들 결정형의 변환방법
CN103204843B (zh) * 2012-01-13 2014-12-31 丽珠医药集团股份有限公司 结晶型艾普拉唑钠乙醇化物及其制备方法
CN103204842B (zh) * 2012-01-13 2014-10-15 丽珠医药集团股份有限公司 结晶型艾普拉唑钠水合物及其制备方法
WO2013114232A1 (en) * 2012-02-02 2013-08-08 Lupin Limited Process for preparation of crystalline form l of ilaprazole
CN102746275B (zh) * 2012-06-21 2014-07-16 丽珠医药集团股份有限公司 结晶型艾普拉唑钠及其制备方法
CN102746277B (zh) * 2012-06-21 2014-05-14 丽珠医药集团股份有限公司 一种结晶形式的艾普拉唑钠及其制备方法
CN103172618B (zh) * 2013-02-27 2014-09-03 丽珠医药集团股份有限公司 艾普拉唑晶型及其制备方法
CN104370886B (zh) * 2014-11-18 2016-05-18 宁夏康亚药业有限公司 艾普拉唑晶型及其制备方法和应用
CN105055342A (zh) * 2015-08-13 2015-11-18 青岛蓝盛洋医药生物科技有限责任公司 一种治疗消化性溃疡的药物艾普拉唑钠组合物冻干粉针剂
CN105055343A (zh) * 2015-08-31 2015-11-18 青岛蓝盛洋医药生物科技有限责任公司 一种治疗胃病的药物艾普拉唑钠组合物冻干粉针剂
CN106749191A (zh) * 2016-12-10 2017-05-31 珠海保税区丽珠合成制药有限公司 艾普拉唑晶型ⅱ及其制备方法
KR101961028B1 (ko) * 2017-10-12 2019-03-21 중앙대학교 산학협력단 일라프라졸을 유효성분으로 함유하는 급성 위염의 예방 또는 치료용 약학 조성물
KR102332996B1 (ko) * 2020-04-13 2021-12-01 중앙대학교 산학협력단 일라프라졸을 유효성분으로 함유하는 장폐색증 예방 또는 치료용 약학조성물
KR20220065235A (ko) 2020-11-13 2022-05-20 주식회사 파마코스텍 일라프라졸 혼형 결정의 신규한 제조방법
KR102250509B1 (ko) * 2020-12-09 2021-05-11 유니셀랩 주식회사 새로운 일라프라졸/자일리톨 공결정
KR20210019469A (ko) 2021-02-02 2021-02-22 주식회사 파마코스텍 일라프라졸 나트륨 결정형 및 신규한 제조방법

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR0179401B1 (ko) * 1994-02-28 1999-03-20 송택선 신규한 5-피롤릴-2-피리딜메틸설피닐벤즈이미다졸 유도체
US6331539B1 (en) 1999-06-10 2001-12-18 3M Innovative Properties Company Sulfonamide and sulfamide substituted imidazoquinolines
RU2232159C2 (ru) * 1999-07-29 2004-07-10 Регентский Совет Университета Калифорнии Производные бензимидазола и фармацевтические композиции, содержащие пролекарство ингибитора протонного насоса
US6627646B2 (en) * 2001-07-17 2003-09-30 Sepracor Inc. Norastemizole polymorphs
KR20040093187A (ko) 2002-03-27 2004-11-04 테바 파마슈티컬 인더스트리즈 리미티드 란소프라졸 다형 및 그것의 제조 방법
CA2597632C (en) 2005-03-25 2012-05-15 Livzon Pharmaceutical Group Inc. Substituted sulfoxide compounds, methods for preparing the same and use thereof
EP1879577A1 (en) * 2005-05-04 2008-01-23 AstraZeneca AB Proton pump inhibitors in the treatment of sleep disturbance due to silent gastro-esophageal reflux

Also Published As

Publication number Publication date
PL2102192T3 (pl) 2013-04-30
EP2102192B1 (en) 2012-11-14
RU2009122242A (ru) 2011-02-10
AU2007341984A1 (en) 2008-07-10
KR20090086121A (ko) 2009-08-10
CA2674347A1 (en) 2008-07-10
JP5315253B2 (ja) 2013-10-16
CA2674358A1 (en) 2008-07-10
NO20092464L (no) 2009-09-28
NZ577509A (en) 2012-01-12
JP5315254B2 (ja) 2013-10-16
MY145936A (en) 2012-05-31
KR20090086615A (ko) 2009-08-13
RU2464270C2 (ru) 2012-10-20
WO2008083341A1 (en) 2008-07-10
ES2398846T3 (es) 2013-03-22
NO20092398L (no) 2009-09-28
US20080200516A1 (en) 2008-08-21
US8592599B2 (en) 2013-11-26
RU2009122241A (ru) 2011-02-10
EP2102192A1 (en) 2009-09-23
AU2007341992A1 (en) 2008-07-10
EP2102191A1 (en) 2009-09-23
AU2007341992B2 (en) 2012-07-05
JP2010514806A (ja) 2010-05-06
WO2008083333A1 (en) 2008-07-10
CN101687848A (zh) 2010-03-31
MX2009006530A (es) 2009-08-18
EP2102191B1 (en) 2012-11-21
HK1140484A1 (en) 2010-10-15
CN101687849A (zh) 2010-03-31
HK1140483A1 (en) 2010-10-15
KR101052387B1 (ko) 2011-07-28
US7989632B2 (en) 2011-08-02
CA2674358C (en) 2013-10-08
CA2674347C (en) 2013-08-06
RU2466129C2 (ru) 2012-11-10
MY146462A (en) 2012-08-15
AU2007341984B2 (en) 2012-07-05
US20110082174A1 (en) 2011-04-07
IL199234A (en) 2013-07-31
MX2009006529A (es) 2009-08-18
US8592600B2 (en) 2013-11-26
CN101687848B (zh) 2013-05-15
NO342530B1 (no) 2018-06-11
KR20110091594A (ko) 2011-08-11
US7999110B2 (en) 2011-08-16
DK2102192T3 (da) 2013-03-04
JP2010514807A (ja) 2010-05-06
NZ577129A (en) 2012-02-24
US20080200517A1 (en) 2008-08-21
PT2102192E (pt) 2013-01-23
US20110046184A1 (en) 2011-02-24
CN101687849B (zh) 2013-05-29

Similar Documents

Publication Publication Date Title
AU2007341992B2 (en) Crystalline forms of solvated ilaprazole
US20080200515A1 (en) Solid state forms of enantiopure ilaprazole
JP6609065B2 (ja) １−（５−（２，４−ジフルオロフェニル）−１−（（３−フルオロフェニル）スルホニル）−４−メトキシ−１ｈ−ピロール−３−イル）−ｎ−メチルメタンアミンの新規な酸付加塩
CN114728899B (zh) 新型三苯基化合物盐
EP3428159A1 (en) Crystalline forms of mesylate salt of pyridinyl amino pyrimidine derivative, preparation methods therefor, and applications thereof
KR20170057441A (ko) Jak 억제제의 바이설페이트의 결정형 및 이의 제조방법
EP3134092A1 (en) Pharmaceutical salts of an orexin receptor antagonist
WO2019078116A1 (ja) 甘味受容体アンタゴニスト
KR20200134928A (ko) 발사르탄/사쿠비트릴 3소듐염 수화물의 결정형 및 그 제조방법
KR102013566B1 (ko) ６-(피페리딘-４-일옥시)-２ｈ-이소퀴놀린-１-온 하이드로클로라이드의 결정성 용매화물
WO2017012771A1 (en) Crystalline filgotinib sulfonic acid addition salts
CN113906018A (zh) 用于治疗皮肤病的缓激肽（bk）b2受体拮抗剂的1-((s)-1-(3-氯-5-氟-2-((4-(1h-吡唑-1-基)-2-甲基喹啉-8-基氧基)甲基)苯基)乙基)-咪唑啶-2,4-二酮衍生物及其相关化合物
BRPI0719624A2 (pt) Formas de estado sólido do ilaprazol racêmico

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees